Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers

Nature Communications

Volumn 5, Issue , 2014, Pages

  Veeraraghavan, Jamunarani ^a   Tan, Ying ^a   Cao, Xi Xi ^a   Kim, Jin Ah ^a   Wang, Xian ^a   Chamness, Gary C ^a   Maiti, Sourindra N ^a   Cooper, Laurence J N ^a   Edwards, Dean P ^a,b   Contreras, Alejandro ^a   Hilsenbeck, Susan G ^a   Chang, Eric C ^a   Schiff, Rachel ^a   Wang, Xiao Song ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESR1 CCDC170 FUSION PROTEIN; ESTROGEN RECEPTOR; HYBRID PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; CARRIER PROTEIN; CCDC170 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; GAB1 PROTEIN, HUMAN; KI 67 ANTIGEN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA;

CANCER; ESTROGENIC COMPOUND; GENETIC VARIATION; MOTILITY; PROTEIN; TUMOR; WOMENS HEALTH;

AMINO TERMINAL SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; CELL MOTILITY; CONTROLLED STUDY; COPY NUMBER VARIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE FUSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; OPEN READING FRAME; PHENOTYPE; SEQUENCE ANALYSIS; TUMOR CELL LINE; TUMOR INVASION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SEPARATION; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OPEN READING FRAMES; PHENOTYPE; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION;

EID: 84907342217     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5577     Document Type: Article

References (49)

1. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
2. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
3. Koivunen, J. P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283 (2008).
4. Bass, A.J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 43, 964-968 (2011).
5. Pierron, G. et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat. Genet. 44, 461-466 (2012).
6. Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231-1235 (2012).
7. Robinson, D. R. et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 17, 1646-1651 (2011).
8. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
9. Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003). (Pubitemid 37071889)
10. Wang, X. S. et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat. Biotechnol. 27, 1005-1011 (2009).
11. Parra, G. et al. Tandem chimerism as a means to increase protein complexity in the human genome. Genome Res. 16, 37-44 (2006). (Pubitemid 43048932)
12. Akiva, P. et al. Transcription-mediated gene fusion in the human genome. Genome Res. 16, 30-36 (2006). (Pubitemid 43048931)
13. Geiss, G. K. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26, 317-325 (2008). (Pubitemid 351355126)
14. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
15. Dunbier, A. K. et al. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. PLoS Genetics 7, e1001382 (2011).
16. Cheang, M. C. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101, 736-750 (2009).
17. Voduc, K. D. et al. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28, 1684-1691 (2010).
18. Tran, B. & Bedard, P. L. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 13, 221 (2011).
19. Dickson, R. B., Bates, S. E., McManaway, M. E. & Lippman, M. E. Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res. 46, 1707-1713 (1986). (Pubitemid 16121496)
20. Gu, H. & Neel, B. G. The "Gab" in signal transduction. Trends Cell Biol. 13, 122-130 (2003).
21. Liu, Y. & Rohrschneider, L. R. The gift of Gab. FEBS Lett. 515, 1-7 (2002). (Pubitemid 34273887)
22. Rajadurai, C. V. et al. Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. J. Cell Sci. 125, 2940-2953 (2012).
23. Shou, J. et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96, 926-935 (2004). (Pubitemid 38868139)
24. de Leeuw, R., Neefjes, J. & Michalides, R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int. J. Breast Cancer 2011, 232435 (2011).
25. Jin, Z. G., Wong, C., Wu, J. & Berk, B. C. Flow shear stress stimulates Gab1 tyrosine phosphorylation to mediate protein kinase B and endothelial nitric-oxide synthase activation in endothelial cells. J. Biol. Chem. 280, 12305-12309 (2005).
26. Campbell, R. A. et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817-9824 (2001).
27. Sakarya, O. et al. RNA-Seq mapping and detection of gene fusions with a suffix array algorithm. PLoS Comput. Biol. 8, e1002464 (2012).
28. Rodrigues, G. A., Falasca, M., Zhang, Z., Ong, S. H. & Schlessinger, J. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol. Cell. Biol. 20, 1448-1459 (2000). (Pubitemid 30069264)
29. Gingeras, T. R. Implications of chimaeric non-co-linear transcripts. Nature 461, 206-211 (2009).
30. Martelli, M. P. et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 174, 661-670 (2009).
31. Maes, B. et al. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. Am. J. Pathol. 158, 2185-2193 (2001). (Pubitemid 32545204)
32. Li, H., Wang, J., Mor, G. & Sklar, J. A neoplastic gene fusion mimics transsplicing of RNAs in normal human cells. Science 321, 1357-1361 (2008).
33. Biernaux, C., Loos, M., Sels, A., Huez, G. & Stryckmans, P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86, 3118-3122 (1995).
34. Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673-8677 (2008).
35. Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
36. Ng, C. K. et al. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J. Pathol. 226, 703-712 (2012).
37. Varela, I. et al. Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol. 11, R100 (2010).
38. McPherson, A. et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput. Biol. 7, e1001138 (2011).
39. Maher, C. A. et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl Acad. Sci. USA 106, 12353-12358 (2009).
40. Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
41. Hahn, Y. et al. Finding fusion genes resulting from chromosome rearrangement by analyzing the expressed sequence databases. Proc. Natl Acad. Sci. USA 101, 13257-13261 (2004). (Pubitemid 39209652)
42. Olshen, A. B., Venkatraman, E. S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004). (Pubitemid 41180205)
43. Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 14, 178-192 (2013).
44. Heiser, L. M. et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl Acad. Sci. USA 109, 2724-2729 (2012).
45. Koboldt, D.C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
46. Zhu, J. et al. The UCSC Cancer Genomics Browser. Nat. Methods 6, 239-240 (2009).
47. Tham, Y. L. et al. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res. Treat. 94, 279-284 (2005).
48. Dowsett, M. et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 103, 1656-1664 (2011).
49. Itamochi, H. et al. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. Int. J. Gynecol. Cancer 24, 61-69 (2014).